Editas takes licence to CRISPR technology amid patent battle

20-12-2016

Editas Medicine, a US genome-editing company, has taken a licence to intellectual property relating to CRISPR technologies for human therapeutics, amid a continuing CRISPR patent battle.


Editas Medicine, CRISPR, human therapeutics, Broad Institute of MIT and Harvard, MIT, University of California

LSIPR